Tazverik Patient Counseling Information

Secondary Malignancies: Advise patients of the increased risk of secondary malignancies. Advise patients to inform their healthcare provider if they experience fatigue, easy bruising, fever, bone pain, or paleness [see Secondary Malignancies under Precautions].
Embryo-Fetal Toxicity: Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Pregnancy under Use in Pregnancy & Lactation].
Advise females of reproductive potential to use effective non-hormonal contraception during treatment with TAZVERIK and for 6 months after the final dose [see Females and Males of Reproductive Potential under Use in Pregnancy & Lactation].
Advise males with female partners of reproductive potential to use effective contraception during treatment with TAZVERIK and for 3 months after the final dose [see Females and Males of Reproductive Potential under Use in Pregnancy & Lactation; Pharmacology: Toxicology: Nonclinical Toxicology under Actions].
Lactation: Advise women not to breastfeed during treatment with TAZVERIK and for 1 week after the final dose [see Lactation under Use in Pregnancy & Lactation].
Drug Interactions: Advise patients and caregivers to inform their healthcare provider of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products. Inform patients to avoid St. John's wort, grapefruit, and grapefruit juice while taking TAZVERIK [see Effect of Other Drugs on TAZVERIK under Interactions].